-
1 Comment
Theranexus Société Anonyme is currently in a long term downtrend where the price is trading 26.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Theranexus Société Anonyme gets an overall score of 1/5.
Exchange | PA |
---|---|
CurrencyCode | EUR |
ISIN | FR0013286259 |
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | 3M |
---|---|
PE Ratio | None |
Target Price | 6.2 |
Beta | 2.51 |
Dividend Yield | None |
Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALTHX.PA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025